Retrospective Cohort Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 18, 2017; 9(20): 884-895
Published online Jul 18, 2017. doi: 10.4254/wjh.v9.i20.884
Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation
Mohammad A B Al-Freah, Carl Moran, Matthew R Foxton, Kosh Agarwal, Julia A Wendon, Nigel D Heaton, Michael A Heneghan
Mohammad A B Al-Freah, Carl Moran, Matthew R Foxton, Kosh Agarwal, Julia A Wendon, Nigel D Heaton, Michael A Heneghan, Institute of Liver Studies, King’s College Hospital, London SE5 9RS, United Kingdom
Author contributions: All authors contributed to this paper.
Institutional review board statement: Ethical approval for interrogation, analysis and publication of this anonymised dataset was given by the Southeast London Research Ethics Committee 3 (previously known as King’s College Hospital Research Ethics Committee).
Informed consent statement: All patients’ details in the dataset for this paper were anonymised. Patients consent was not deemed necessary by the Southeast London Research Ethics Committee 3 (previously known as King’s College Hospital Research Ethics Committee) giving the retrospective design of the study.
Conflict-of-interest statement: No conflicts of interest relevant to this article were reported. Michael A Heneghan is supported by an educational grant from The Kelly Group.
Data sharing statement: Anonymised dataset will be made available on request from Mohammad Al-Freah at alfreah@yahoo.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Michael A Heneghan, Consultant Hepatologist, Institute of Liver Studies, King’s College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. michael.heneghan@nhs.net
Telephone: +44-203-2991661 Fax: +44-203-2993167
Received: November 4, 2016
Peer-review started: November 8, 2016
First decision: November 30, 2016
Revised: May 12, 2017
Accepted: May 30, 2017
Article in press: May 31, 2017
Published online: July 18, 2017
Core Tip

Core tip: The prevalence and impact of comorbidity on waiting list (WL) and post-transplant survival is unknown in patients who had liver retransplantation. This study identified comorbidity(ies) were common (56%) in this cohort, most with renal impairment. WL mortality was higher in patients with ≥ 1 comorbidity and model for end stage liver disease (MELD) score ≥ 18. Post-transplant survival was inferior in patients with ≥ 1 comorbidity, MELD score ≥ 18 and in patients who required organ support prior to retransplantation. Comorbidity increases WL and post-transplant mortality. Patients with comorbidity or MELD ≥ 18 may benefit from earlier retransplantation.